BIOMAT Database Logo BIOMAT Database Logo

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. 2011

Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Georgia 30322, USA. paul.spearman@emory.edu

BACKGROUND A key missing element in the development of a successful human immunodeficiency virus (HIV) vaccine is an immunogen that can generate broadly cross-neutralizing antibodies against primary isolates of the virus. METHODS This phase 1 clinical trial employed a DNA prime and subunit envelope protein boost in an attempt to generate cellular and humoral immune responses that might be desirable in a protective HIV vaccine. Priming was performed via intramuscular injection with gag and env DNA adsorbed to polylactide coglycolide microspheres, followed by boosting with a recombinant trimeric envelope (Env) glycoprotein delivered in MF59 adjuvant. RESULTS The DNA prime and protein boost were generally safe and well-tolerated. Env-specific CD4(+) cellular responses were generated that were predominantly detected after Env protein boosting. Neutralizing antibody responses against the homologous SF162 viral isolate were remarkably strong and were present in the majority of vaccine recipients, including a strong response against CD4-induced epitopes on gp120. Despite the promising potency of this vaccine approach, neutralization breadth against heterologous tier 2 strains of HIV-1 was minimal. CONCLUSIONS Potent neutralization against neutralization-sensitive strains of HIV is achievable in humans through a DNA prime, recombinant oligomeric Env protein boost regimen. Eliciting substantial breadth of neutralization remains an elusive goal. BACKGROUND NCT00073216.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques.
November 2001, Immunology letters,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.
November 2005, Microbes and infection,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine.
August 2011, Expert review of vaccines,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.
February 2023, mBio,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.
July 2023, Cell reports,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
May 2015, Journal of virology,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region.
September 2019, Molecular therapy. Methods & clinical development,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
January 2016, Expert review of vaccines,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies.
September 2018, Retrovirology,
Paul Spearman, and Michelle A Lally, and Marnie Elizaga, and David Montefiori, and Georgia D Tomaras, and M Juliana McElrath, and John Hural, and Stephen C De Rosa, and Alicia Sato, and Yunda Huang, and Sharon E Frey, and Paul Sato, and John Donnelly, and Susan Barnett, and Lawrence J Corey, and
HIV: Sequential vaccine elicits broadly neutralizing antibodies.
November 2016, Nature reviews. Drug discovery,
Copied contents to your clipboard!